Yes, meloxicam can cause gas and broader digestive issues, though flatulence is among the less common complaints compared with nausea, indigestion, and abdominal pain. Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that works by suppressing prostaglandin production, and prostaglandins are not just pain signals; they are also part of the gut's protective and motility-regulating machinery. That dual role explains why a drug taken for joint pain can produce burping, bloating, cramping, and loose stools. This explainer covers the pharmacology behind those symptoms, how often they occur, who is at higher risk, and what to do about them.

How meloxicam disrupts the gut

Meloxicam inhibits cyclooxygenase enzymes, primarily COX-2, which convert arachidonic acid into prostaglandins. Most people know prostaglandins as mediators of inflammation and pain. Less widely appreciated is that the gut uses prostaglandins constitutively, meaning continuously and not just during injury. Prostaglandin E2 and prostacyclin support mucus and bicarbonate secretion, maintain mucosal blood flow, and help regulate the rhythm of smooth-muscle contractions in the stomach and intestine.

When meloxicam blunts prostaglandin synthesis, several things follow. Mucus output can fall, thinning the protective layer over the stomach lining. Bicarbonate secretion may decline, leaving acid less buffered at the mucosal surface. Mucosal blood flow can drop, reducing the delivery of oxygen and repair factors to the epithelium. Each of these shifts makes the lining more vulnerable, and that vulnerability can register as burning, early fullness, or nausea.

Separately, altered prostaglandin signaling can change how the gut moves. Motility becomes less coordinated, which allows gas to pool and distend the bowel rather than move forward efficiently. Some of the gas itself comes from fermentation of undigested carbohydrate by colonic bacteria when transit slows. So the flatulence and bloating some users report is not gas generated by the drug directly; it is gas that accumulates because clearance and motility have changed. Another contributor is that NSAIDs can alter the gut microbiome composition, shifting bacterial populations in ways that increase fermentation and gas production. That same microbial disruption is part of why NSAID use is associated with flares in inflammatory bowel disease.

For meloxicam specifically, the COX-2 preference matters. Older nonselective NSAIDs like ibuprofen and naproxen inhibit both COX-1 and COX-2. COX-1 is the isoform most tied to gastric protection, so sparing it should, in theory, spare the stomach. In practice, meloxicam's selectivity is dose-dependent: at lower doses it leans COX-2, and as the dose rises it behaves more like a nonselective NSAID. That is one reason gastrointestinal risk with meloxicam is not zero and is not uniform across patients.

How common are gas and digestive symptoms?

Gastrointestinal complaints are the most frequently reported adverse effects of NSAID therapy as a class. In meloxicam's product labeling, the listed gastrointestinal adverse reactions include dyspepsia, nausea, abdominal pain, diarrhea, constipation, flatulence, and vomiting. Dyspepsia (upper abdominal discomfort or burning) is generally the most common of these, followed by nausea and abdominal pain. Flatulence appears on the label as a reported reaction but is not typically the leading complaint; patients more often describe indigestion, stomach upset, or loose stools. Exact incidence figures for individual symptoms are not consistently published across meloxicam trials, so specific percentages should not be treated as reliable.

The more clinically important statistic is the rate of serious gastrointestinal events. NSAID-related ulcers, bleeding, and perforation occur in a measurable fraction of long-term users, and the risk rises with dose and duration. Meloxicam's COX-2 preference lowers but does not eliminate that risk. This is why even patients who never notice gas or indigestion still warrant attention to warning signs.

A practical way to frame frequency: mild upper-GI symptoms are common enough that they are a routine counseling point when meloxicam is prescribed. Flatulence specifically is reported but less prominent, and many patients who experience it describe it as mild and intermittent rather than a reason to stop therapy. For a drug taken once daily for chronic conditions like osteoarthritis or rheumatoid arthritis, the exposure is prolonged, which is why even low-grade symptoms deserve tracking rather than dismissal.

Edge cases: who is more vulnerable

Several factors amplify meloxicam's gastrointestinal effects. Age is one: adults over 65 have a higher baseline rate of NSAID-related GI complications and are often on lower body weight and lower clearance. A prior history of ulcer, GI bleeding, or inflammatory bowel disease raises risk substantially. Concurrent use of corticosteroids, anticoagulants, or selective serotonin reuptake inhibitors compounds bleeding risk. Smoking and heavy alcohol use independently irritate the gastric lining and add to the burden.

Kidney function is another edge case. Meloxicam is cleared partly by the kidneys, and reduced renal function can raise drug exposure. Dehydration, heart failure, and liver impairment also change how the body handles the drug and how well the gut tolerates it. Patients with these conditions may notice more pronounced symptoms at the same dose that another person tolerates easily.

There is also a timing dimension. Symptoms often appear within the first days to weeks of starting therapy or after a dose increase, but they can emerge months later in someone whose dose and routine have not changed. A new GI symptom in a long-term meloxicam user should not be assumed to be unrelated to the drug. The counterintuitive detail here is that absence of early symptoms does not predict long-term tolerance; some patients develop problems only after sustained exposure.

Black or tarry stools, or vomit that looks like coffee grounds (possible GI bleeding) Severe or persistent abdominal pain, especially if it localizes or worsens after eating Unexplained fatigue, pale skin, or shortness of breath (possible anemia from slow blood loss) Difficulty swallowing, or food that feels stuck Swelling of the face, lips, or tongue, or wheezing (allergic reaction)

These warrant prompt medical attention rather than watchful waiting.

Misconceptions worth correcting

One common misconception is that COX-2-selective drugs are "stomach-safe" and therefore cannot cause digestive symptoms. Selectivity reduces the risk of ulcers relative to nonselective NSAIDs, but it does not abolish dyspepsia, nausea, or flatulence, and it does not eliminate ulcer risk entirely, particularly at higher doses or with prolonged use. Another misconception is that taking meloxicam with food fully protects the stomach. Food reduces the local irritation of the tablet contacting the lining and may ease nausea, but it does not change the systemic prostaglandin suppression that drives most of the GI effects.

A third misconception is that gas means the drug is "not working" or is causing an allergy. Flatulence and bloating are common, non-allergic effects of altered motility and fermentation, not a sign of immune reaction. A true allergy would look like rash, hives, facial swelling, or breathing difficulty, which is a different problem entirely. Finally, some people assume that because meloxicam is long-acting and taken once daily, it is gentler than short-acting NSAIDs. Long duration means longer continuous exposure, which for chronic use can matter more than the peak concentration of a short-acting drug.

Alternatives and how they compare

When GI symptoms are troublesome, clinicians sometimes switch to a different NSAID, add a gastroprotective agent, or move to a non-NSAID option. The table below compares common alternatives on gastrointestinal tolerability, not on efficacy for any specific condition, which varies by patient.

Option GI tolerability profile Key considerations
Meloxicam Moderate; COX-2-leaning, dose-dependent selectivity Once-daily; GI risk rises with dose and duration
Ibuprofen Lower selectivity; more dyspepsia at higher doses Short-acting; frequent dosing
Naproxen Nonselective; GI risk comparable to other nonselective NSAIDs Longer half-life; twice-daily typical
Celecoxib More COX-2 selective than meloxicam Still carries GI and cardiovascular risk
Acetaminophen Minimal direct gastric irritation Weaker anti-inflammatory effect; liver limits
Topical NSAID Very low systemic exposure Useful for localized joint pain only
Physical therapy / exercise No GI risk Requires time and adherence

The main trade-off is that reducing GI risk often means reducing anti-inflammatory potency or changing route. Topical formulations minimize systemic exposure but only work for accessible, localized joints. Acetaminophen spares the stomach but does not address inflammation the way an NSAID does. Any switch should account for cardiovascular and kidney risk as well, because those risks differ across these options and are not captured in a GI-focused table.

A typical timeline of GI effects

Symptoms do not follow a single script, but the general time course below reflects common patterns. Individual variation is wide, and this table is descriptive, not predictive.

Timeframe What patients often notice
First 1–3 days Mild nausea, stomach awareness, or early fullness
First 1–2 weeks Dyspepsia, burping, or loose stools may appear or settle
Weeks 2–6 Tolerance may develop for mild symptoms, or they may persist
Months 1–3 Risk of ulceration accumulates with continued use
Beyond 3 months Serious GI events become more likely with dose and duration
Any time New symptoms should not be assumed unrelated to the drug

The key pattern is that early mild symptoms often improve as the body adapts, while serious events tend to emerge later and are not preceded by a predictable warning in every case.

Practical steps and thresholds

If gas or digestive symptoms appear on meloxicam, the first step is to log them: what symptom, when it started, whether it correlates with meals, and whether it is mild, moderate, or interfering with daily life. A simple written record over one to two weeks gives a clinician far more to work with than a vague report.

Second, review the medication list for add-ons that compound GI risk, including corticosteroids, anticoagulants, aspirin, and SSRIs. Third, discuss timing and food with a pharmacist or prescriber; taking the dose with a meal may ease local irritation even though it does not change systemic effects. Fourth, do not add over-the-counter NSAIDs on top of meloxicam, because combined NSAID use raises GI and kidney risk without adding benefit.

Thresholds for seeking care: any black or tarry stool, vomiting blood or coffee-ground material, severe abdominal pain, or unexplained anemia symptoms warrant urgent evaluation. Persistent dyspepsia lasting more than a couple of weeks, or symptoms that interfere with eating or sleep, justify a call to the prescriber. Mild, intermittent gas that does not affect daily life can reasonably be monitored, but it should still be mentioned at the next visit.

A gastroprotective agent such as a proton pump inhibitor is sometimes co-prescribed for patients at higher ulcer risk; that decision belongs to the prescriber and depends on the individual's risk profile, not on the presence of gas alone.

Limits of what the evidence can say

The honest limitation is that meloxicam's label lists flatulence and other GI reactions as reported adverse events without reliably published per-symptom incidence rates, so anyone quoting a precise percentage for gas is likely overstating certainty. The mechanistic story, prostaglandin suppression leading to reduced mucosal protection and altered motility, is well established and stable. The clinical frequency of specific mild symptoms is less precisely characterized and varies by population, dose, and duration.

What can be said with confidence is that digestive complaints are the dominant adverse-effect category for NSAIDs, that meloxicam's COX-2 preference lowers but does not remove serious GI risk, and that gas and bloating are plausible consequences of motility and microbiome changes rather than direct drug-generated gas. Anyone with new or worsening GI symptoms on meloxicam should treat them as worth reporting, not as something to simply endure.